Key result
Low-dose alteplase shows no benefit over standard-dose therapy for 90-day functional recovery.
Why the study?
Clinicians sometimes administer alteplase doses below the guideline-recommended regimen in routine stroke care, yet the patient characteristics underlying these decisions and their relationship with clinical outcomes remain incompletely understood.
Does clinician-selected low-dose or medium-dose intravenous alteplase affect good 90-day functional outcome (mRS 0-2) compared to standard-dose alteplase in Taiwanese patients with acute ischemic stroke?
Cohort (n=418)
Assessors were not formally blinded by protocol, but alteplase dose information was not routinely reviewed or used during assessment.
No
Does clinician-selected low-dose or medium-dose intravenous alteplase affect good 90-day functional outcome (mRS 0-2) compared to standard-dose alteplase in Taiwanese patients with acute ischemic stroke?
In routine Taiwanese acute ischemic stroke care, clinician selection of reduced-dose alteplase is driven by older age and diabetes mellitus, and crude differences in 90-day functional outcomes across dose categories are explained by baseline patient risk profiles rather than independent dose effects.
Answers are grounded in this paper and cite their sources.
No independent outcome benefit from low-dose alteplase; leaves open whether RCTs can identify subgroups warranting reduced dosing.
PURPOSE: Clinicians sometimes administer alteplase doses below the guideline-recommended regimen in routine stroke care, yet the patient characteristics underlying these decisions and their relationship with outcomes remain incompletely understood. This study aimed to identify factors associated with clinician-selected alteplase dosing and to examine the relationship between dose category and clinical outcomes. METHOD: We retrospectively studied 418 Taiwanese patients with acute ischemic stroke who received intravenous alteplase without endovascular thrombectomy between January 2017 and June 2022. Administered doses were categorized as low (0.46-0.64 mg/kg), medium (0.67-0.84 mg/kg), or standard (0.85-0.94 mg/kg). Multinomial logistic regression identified factors associated with clinician-selected dose, and logistic regression evaluated good 90-day functional outcome, defined as a modified Rankin Scale score of 0-2. FINDING: Older age was independently associated with low-dose rather than standard-dose treatment (adjusted odds ratio [aOR] per year, 1.07; 95% confidence interval [CI], 1.04-1.09). Diabetes mellitus was associated with both medium-dose (aOR, 1.84; 95% CI, 1.02-3.29) and low-dose treatment (aOR, 2.71; 95% CI, 1.60-4.60). Good 90-day outcome occurred in 44.0%, 53.6%, and 67.9% of the low-, medium-, and standard-dose groups, respectively. However, dose category was not independently associated with good outcome after adjustment for baseline characteristics and prestroke antithrombotic therapy. Hemorrhagic outcome estimates were imprecise because symptomatic intracranial hemorrhage events were uncommon. CONCLUSION: Real-world alteplase dosing primarily reflected baseline patient risk profiles and treatment-selection patterns. Crude differences in 90-day functional outcome between dose groups were attenuated after adjustment and should therefore be interpreted as treatment-selection associations rather than causal treatment effects.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) conducted a cohort in Acute ischemic stroke treated with intravenous alteplase monotherapy (n=418). Low-dose (0.46-0.64 mg/kg) or medium-dose (0.67-0.84 mg/kg) intravenous alteplase vs. Standard-dose intravenous alteplase (0.85-0.94 mg/kg) was evaluated on Good 90-day functional outcome (modified Rankin Scale score 0-2) for low-dose vs. standard-dose alteplase (OR 1.02, 95% CI 0.57-1.83, p=0.938). Low-dose alteplase was not independently associated with good 90-day functional outcome compared with standard-dose alteplase after multivariable adjustment.
Synapse has enriched 10 related papers. Consider them for comparative context: